Introduction
Methods
Study participants
Measurement of circulating senescence biomarkers
Clinical and molecular outcome measures
Statistical methods
Results
Participant demographic and clinical characteristics
Control (n = 85) | IPF (n = 95) | p-value | |
---|---|---|---|
Age, years
mean ± SD | 63.40 ± 10.48 | 64.81 ± 8.72 | 0.411* |
Sex, females
n (%) |
45 (52.9%)
|
33 (34.7%)
|
0.014
†
|
BMI, Kg/m
2
Mean ± SD | 29.51 ± 6.40 | 30.38 ± 5.90 | 0.202* |
Ever Smoked (> 100)
n (%) | 5 (6.5%) | 11 (11.8%) | 0.236† |
Pack Years
Mean ± SD | 36.75 ± 35.31 | 27.26 ± 21.98 | 0.289* |
FVC, % predicted
Mean ± SD |
94.51 ± 12.97
|
68.42 ± 14.59
|
< 0.001
*
|
DLCO, % predicted
Mean ± SD |
83.66 ± 16.62
|
52.67 ± 16.56
|
< 0.001
*
|
FEV1, % predicted
Mean ± SD |
95.20 ± 12.66
|
75.59 ± 16.05
|
< 0.001
*
|
SGRQ
Mean ± SD |
12.48 ± 15.52
|
40.03 ± 19.67
|
< 0.001
*
|
SF-12
Mean ± SD |
48.09 ± 11.28
|
38.15 ± 10.47
|
< 0.001
*
|
6MWT, meters
Mean ± SD |
418.18 ± 118.42
|
387.16 ± 89.15
|
0.004
*
|
Biomarkers of cellular senescence in participants with IPF and controls
Protein | Control n = 85 | IPF n = 95 | p-value |
---|---|---|---|
Activin A |
355.3 ± 193.9
|
418.4 ± 183.9
|
0.009
|
ADAMTS13 |
932465.0 ± 431528.9
|
796302.1 ± 368128.0
|
0.022
|
Eotaxin |
1148.9 ± 469.5
|
1440.8 ± 667.9
|
0.002
|
Fas | 8688.8 ± 6202.1 | 7706.4 ± 2753.8 | 0.389 |
GDF15 |
1463.2 ± 1542.3
|
2050.8 ± 1343.6
|
< 0.001
|
GROα | 246.1 ± 311.3 | 198.0 ± 99.5 | 0.331 |
ICAM1 |
238606.1 ± 183090.8
|
259886.9 ± 161879.8
|
0.007
|
IL1α | 6.7 ± 6.7 | 9.5 ± 15.0 | 0.112 |
IL6 | 10.3 ± 16.8 | 9.7 ± 7.7 | 0.219 |
IL7 |
3.1 ± 1.9
|
3.7 ± 1.9
|
0.022
|
IL8 | 6.8 ± 4.3 | 9.0 ± 14.8 | 0.134 |
IL10 |
22.1 ± 20.6
|
35.0 ± 42.5
|
0.015
|
IL15 | 1.5 ± 1.3 | 1.5 ± 1.2 | 0.616 |
MCP1 |
279.6 ± 88.6
|
363.2 ± 123.8
|
< 0.001
|
MDC |
454.8 ± 149.7
|
611.8 ± 215.3
|
< 0.001
|
MIP1α | 17.0 ± 16.6 | 22.1 ± 37.8 | 0.345 |
MIP1β | 370.0 ± 1724.5 | 162.4 ± 59.5 | 0.629 |
MMP1 |
764.3 ± 813.7
|
772.9 ± 433.2
|
0.017
|
MMP7 |
2875.3 ± 2516.3
|
3828.2 ± 1591.5
|
< 0.001
|
MMP9 | 54523.0 ± 70865.2 | 49,906 ± 56381.2 | 0.582 |
MPO |
82905.8 ± 111974.0
|
95750.7 ± 86099.0
|
0.031
|
OPN | 72451.1 ± 75720.1 | 52389.8 ± 55664.1 | 0.086 |
PAI1 | 20178.6 ± 11816.0 | 22684.1 ± 13130.5 | 0.188 |
PARC |
53061.1 ± 32883.8
|
72900.6 ± 41964.7
|
< 0.001
|
RAGE |
1732.7 ± 829.4
|
1153.8 ± 554.2
|
< 0.001
|
RANTES |
23107.9 ± 15665.1
|
32923.4 ± 30574.4
|
0.004
|
SOST | 442.8 ± 223.6 | 402.9 ± 207.6 | 0.183 |
TARC |
433.1 ± 126.7
|
726.8 ± 720.0
|
< 0.001
|
TNFα | 9.2 ± 7.2 | 8.3 ± 5.3 | 0.466 |
TNFR1 | 1518.2 ± 658.4 | 1370.0 ± 515.7 | 0.232 |
TNFR2 | 3608.3 ± 1910.0 | 3312.8 ± 1670.1 | 0.275 |
VEGFA | 42.3 ± 18.8 | 39.1 ± 16.2 | 0.380 |
Associations of senescence biomarkers with clinical and patient-centered outcomes
Association of plasma biomarkers of senescence with gene expression levels in the lung
Protein | Gene Symbol | Unadjusted r-value | Unadjusted p-value | Adjusted r-value | Adjusted p-value |
---|---|---|---|---|---|
Activin A |
INHBA
| -0.14 | 0.052 | -0.13 | 0.074 |
ADAMTS13 |
ADAMTS13
| 0.05 | 0.489 | 0.05 | 0.536 |
Eotaxin |
CCL11
|
0.28
|
< 0.001
|
0.18
|
0.017
|
GDF15 |
GDF15
|
0.24
|
0.001
|
0.21
|
0.005
|
MCP1 |
CCL2
| 0.11 | 0.144 | 0.10 | 0.172 |
MDC |
CCL22
|
0.29
|
< 0.001
|
0.28
|
< 0.001
|
MMP7 |
MMP7
|
0.44
|
< 0.001
|
0.42
|
< 0.001
|
PARC |
CCL18
|
0.34
|
< 0.001
|
0.30
|
< 0.001
|
RAGE |
AGER
|
0.38
|
< 0.001
|
0.39
|
< 0.001
|
TARC |
CCL17
|
0.32
|
< 0.001
|
0.26
|
< 0.001
|